Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222878 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
A Phase 1 study of Alzheimer Disease and Epilepsy, sponsored by NeuroPro Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT07222878: Recruiting Phase 1 study of Alzheimer Disease and Epilepsy, sponsored by NeuroPro Therapeutics.
NCT07222878 is a Phase 1 study of Alzheimer Disease and Epilepsy that is actively recruiting participants, run by NeuroPro Therapeutics. The registered enrollment target is 8 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222878, a Phase 1 study of Alzheimer Disease and Epilepsy, is actively recruiting participants, sponsored by NeuroPro Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Primary Outcome
Plasma NPT 2042 PK endpoints including the Cmax (NPT 2042 only).
Conditions Studied
Interventions
- DRUG NPT 2042 (Reference formula/Formulation 1)
- DRUG NPT 2042 (Test formula/Formulation 2)
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2025-11-15 |
| Phase | Phase 1 |
What NCT07222878 shows while recruiting
NCT07222878 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which NPT 2042 (Reference formula/Formulation 1) is the first listed.
NCT07222878 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT07222878 about?
NCT07222878 is a clinical study titled "Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042". A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
What is the current status of trial NCT07222878?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-09-29. Estimated completion is 2025-11-15.
What conditions does trial NCT07222878 study?
This clinical trial studies the following conditions: Alzheimer Disease, Epilepsy, Epilepsy Intractable.
What interventions are being tested in trial NCT07222878?
The interventions under investigation include: NPT 2042 (Reference formula/Formulation 1) (DRUG), NPT 2042 (Test formula/Formulation 2) (DRUG).
Who is sponsoring clinical trial NCT07222878?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222878 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222878's enrollment target sits among peer trials
8 296th of 306 higher than 8 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
-
R21 Roche: 3-Way Tau Tracers in AD
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI